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Using an Instrumental Variable to Test for
Unmeasured Confounding
Zijian Guoa,Jing Chengb, Scott A. Lorchc, Dylan S. Smalla
An important concern in an observational study is whether or not there is unmeasured confounding, i.e.,
unmeasured ways in which the treatment and control groups differ before treatment that affect the outcome.
We develop a test of whether there is unmeasured confounding when an instrumental variable (IV) is
available. An IV is a variable that is independent of the unmeasured confounding and encourages a subject
to take one treatment level vs. another, while having no effect on the outcome beyond its encouragement
of a certain treatment level. We show what types of unmeasured confounding can be tested for with an IV
and develop a test for this type of unmeasured confounding that has correct type I error rate. We show
that the widely used Durbin-Wu-Hausman (DWH) test can have inflated type I error rates when there is
treatment effect heterogeneity. Additionally, we show that our test provides more insight into the nature of
the unmeasured confounding than the DWH test. We apply our test to an observational study of the effect of
a premature infant being delivered in a high-level neonatal intensive care unit (one with mechanical assisted
ventilation and high volume) vs. a lower level unit, using the excess travel time a mother lives from the
nearest high-level unit to the nearest lower-level unit as an IV. Copyright c⃝ 0000 John Wiley & Sons, Ltd.
Keywords: instrumental variables; observational study; confounding; comparative effectiveness
1. Introduction
Randomized controlled studies are the gold standard to compare the effects of treatments between different
treatment groups. Unfortunately, randomized controlled studies are often not feasible because of cost or ethical
constraints. When randomized studies are not feasible, observational studies provide important evidence about
the comparative effectiveness of different treatments. Since treatments were not randomly assigned, a major
concern in an observational study is confounding, meaning that the treatment groups may differ before treatment
in ways that also affect the outcome. If the confounders are measured, these differences can be adjusted for by
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matching, stratification or regression[1]. However, there is often concern that there are unmeasured ways in which
the treatment groups differ that affect the outcome, meaning that there is unmeasured confounding. Even when
there is unmeasured confounding, it is possible to obtain a consistent estimate of the causal effect of treatment
for a certain sub-population (the compliers) if an instrumental variable (IV) can be found. An IV is a variable
that (1) is independent of the unmeasured confounding; (2) encourages, but does not force, a subject to take one
treatment level vs. another; and (3) has no effect on the outcome beyond its encouragement of a certain treatment
level. For discussions of IVs, see [2, 3, 4, 5, 6, 7, 8, 9]. In this paper, we develop a method for using an IV to
test whether there is unmeasured confounding. Detecting whether there is unmeasured confounding is valuable in
many studies because if unmeasured confounding is found in a given study, it suggests that for studying related
questions, researchers should either try to measure more confounders or seek to find IVs.
The existing and widely used test for whether there is unmeasured confounding using an IV is the Durbin-Wu-
Hausman endogeneity test, hereafter called the DWH test, independently proposed by Dur bin [10], Wu [11] and
Hausman[12]. The DWH test compares an estimate of the average treatment effect under the assumption that there
is no unmeasured confounding to an estimate of the average treatment effect using an IV that allows for unmeasured
confounding. The IV estimate of the average treatment effect is assumed to be consistent so that a significant
difference between it and the estimate that assumes no unmeasured confounding is taken as evidence of unmeasured
confounding. The two estimates of the average treatment effect in the DWH test assume that the treatment effect is
homogeneous, meaning that the treatment effect is not different by covariates; see [13, 4, 14, 15, 16] for discussion
of homogeneity assumptions. [15] noted that if the DWH test rejects, one cannot be sure whether it is because of
unmeasured confounding or treatment effect heterogeneity. Extensions to the conventional DWH test have been
developed that allow for heteroskedasticity[17, 18], but these tests all have the property that if they reject, one
cannot sure be sure whether it is because of unmeasured confounding or treatment effect heterogeneity.
In this paper, we develop a test that distinguishes between unmeasured confounding and treatment effect
heterogeneity. We discuss what types of unmeasured confounding can be tested for and provide a test with correct
type I error rate for the testable types of unmeasured confounding. In addition to having the advantage over the
DWH test of having correct type I error rate for testing unmeasured confounding when there is treatment effect
heterogeneity, our testing approach also provides more insight into the nature of the unmeasured confounding by
providing separate tests for two different types of unmeasured confounding. In the DWH test, these two types of
unmeasured confounding are lumped together.
The motivating application for our work is an observational study of neonatal care that seeks to estimate the
effect on mortality of a premature infant being delivered in a high-level neonatal intensive care unit (NICU) vs.
a lower-level NICU. A high-level NICU is defined as a NICU that has the capacity for sustained mechanical
assisted ventilation and delivers at least 50 premature infants per year. Estimating the effect of being delivered
at a high-level NICU is important for determining the value of a policy of regionalization of perinatal care that
aims for premature infants to be mostly delivered in high-level NICUs [19]. Regionalization of perinatal care was
developed in the 1970s along with the expansion of neonatal technologies, but by the 1990s, regionalization began
to weaken in many areas of the United States [20]. The difficulty in studying the causal effect of a premature infant
being delivered in a high-level vs. a lower-level NICU is confounding by indication – the mother and the mother’s
physician may try harder to deliver an infant at a high level NICU if the infant is at higher risk of mortality. In our
data from Pennsylvania (described in Section 7), the unadjusted death rate in high-level NICUs is higher than in
low-level NICUs, 23 vs. 12 deaths per 1000 deliveries. Since it is unlikely that high level NICUs are worse than low
level NICUs, the higher unadjusted death rate in high level NICUs probably reflects confounding by indication.
Our data contains a number of potential confounders, including birth weight, month prenatal care started, mother’s
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education and whether the mother went into labor prematurely. After adjustment for measured confounders by
propensity score matching, the death rate is 0.5 deaths per 1000 deliveries lower in high-level NICUs [21].
However, we are concerned about unmeasured potential confounders, such as the severity of a mother’s comorbid
condition or an infant’s antenatal condition, lab results, fetal heart tracing results, the compliance of the mother to
medical treatment and the physician’s history with the mother. These variables are known to the physicians who
assess a mother’s probability of delivering a high-risk infant. Based on this probability, the physicians then play
a role in deciding where the mother should deliver. To attempt to deal with the problem of potential unmeasured
confounding, we have collected data on a proposed IV, the excess travel time that a mother lives from the nearest
high-level NICU compared to the nearest lower-level NICU; specifically, the IV is whether or not the mother’s
excess travel time is less than or equal to 10 minutes. Excess travel time to a hospital delivering speciality care has
been used as an IV in other medical settings, such as studies of the effect of cardiac catheterization on survival in
patients who suffered an acute myocardial infarction[22]. In obstetric care, prior work suggests that women tend
to deliver at the closest hospital so that we expect that excess travel time will have a strong effect on where the
infant is delivered[23]. We discuss in Section 7 reasons for thinking excess travel time is a valid IV. Our goal in
this paper is to use the putative IV excess travel time to test whether there is unmeasured confounding in the study
of the effect of high-level vs. lower-level NICUs. If unmeasured confounding is found, it suggests that previous
studies of the effect of high-level vs. lower-level NICUs that assumed no unmeasured confounding provided biased
estimates and that future studies of the effect of NICU level on mortality and related medical questions should seek
to measure more confounders and/or find and measure IVs. Related medical questions include the effects of high
level NICUs on complications, length of stay and readmissions, which have not yet been studied systematically.
The rest of the paper is organized as follows. In Section 2, we set up the causal framework and introduce notation
and assumptions. In Section 3, we discuss what type of unmeasured confounding can be tested for when there are
heterogeneous treatment effects. In Section 4, we develop our method for testing for unmeasured confounding
using an IV. In Section 5, we discuss the DWH test and how it performs when there are heterogeneous treatment
effects. In Section 6, we present a simulation study comparing our method to the DWH test. In Section 7, we apply
our test to the study of the effect of high-level vs. lower-level NICUs. Finally, we provide conclusions in Section 8.
2. The Framework
2.1. Notation
The IV Z and the treatment A are assumed to each be binary, where level 0 of the treatment is considered the
“control” (lower-level NICU in our application) and level 1 is considered to be the “treatment” (high-level NICU in
our application). We letZ denote theN -dimensional vector of IV values for allN subjects, with individual elements
Zi = z ∈ {0, 1} for subject i; level 1 of the IV is assumed to encourage receiving the treatment compared to level
0. Let Az be the N -dimensional vector of potential treatment under IV assignment z, with individual element
Azi = a ∈ {0, 1} according to whether subject i would take the control or treatment under z. We let Yz,a be the
vector of potential responses that would be observed under IV levels z and treatment levels a, with individual
element Y z,ai for subject i. {Y z,ai } and {Azi } are “potential” responses and treatments in the sense that we can
observe only one value in each set. We let Yi andAi be the corresponding observed outcome and treatment variables
for subject i. We letXi denote the measured confounders for subject i. We assume thatXi includes an intercept.
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2.2. Assumptions
We make the same assumptions as [2] within strata of the measured confoundersX.
1. Stable unit treatment value assumption (SUTVA)[29]: (a) If zi = z
′
i, thenA
z
i = A
z
′
i . (b) If zi = z
′
i and ai = a
′
i,
then Y z,ai = Y
z
′
,a
′
i . This assumption allows us to write Y
z,a
i and A
z
i as Y
z,a
i and A
z
i , respectively, for subject
i.
2. IV is independent of unmeasured confounding: Conditional on X, for a randomly chosen subject, the IV Z is
independent of the vector of potential responses and treatments (Y 0,0, Y 0,1, Y 1,0, Y 1,1, A0, A1).
3. Exclusion restriction: For each subject i, Y z,ai = Y
z
′
,a
i for all z, z
′
and a, i.e., the IV level affects outcomes
only through its effect on treatment level. This assumption allows us to define Y ai ≡ Y 0,ai = Y 1,ai for a = 0, 1.
4. IV affects treatment: P (A = 1|Z = 1) > P (A = 1|Z = 0).
5. Monotonicity: A1i ≥ A0i for all i. This assumption says that there is no one who would always do the opposite
of what the IV encourages, i.e., no one who would not take the treatment if encouraged to do so by the IV level
but would take the treatment if not encouraged by the IV level.
We further make the consistency assumption[30]:
6. Consistency: No matter how subject i is administered the treatment, the potential outcome is the same so that:
Yi = AiY
1
i + (1−Ai)Y 0i ,
where Yi and Ai are the observed outcome and treatment for subject i.
2.3. Compliance Class
Based on a subject’s joint values of potential treatment (A0i , A
1
i ), a subject can be classified into one of four latent
compliance classes [2]:
Ci =

nt (never-taker) if (A0i , A
1
i ) = (0, 0)
co (complier) if (A0i , A
1
i ) = (0, 1)
at (always-taker) if (A0i , A
1
i ) = (1, 1)
de (defier) if (A0i , A
1
i ) = (1, 0)
Under the monotonicity assumption, there are no defiers. We can observe only one of A0i and A
1
i , so a
subject’s compliance class is not observed directly but it can be partially identified based on IV level and
observed treatment as shown in Table 1. Based on Table 1, the following quantities are identified under
assumptions 1− 6 based on the observable data: P (C = at) = P (A = 1|Z = 0), P (C = nt) = P (A = 0|Z = 1),
P (C = co) = 1− P (A = 1|Z = 0)− P (A = 0|Z = 1), E(Y 1|C = at) = E(Y |Z = 0, A = 1), E(Y 0|C = nt) =
E(Y |Z = 1, A = 0), E(Y 1|C = co) = E(Y |Z=1,A=1)−[P (C=at)/{P (C=at)+P (C=co)}]E(Y |Z=0,A=1)P (c=co)/{P (C=at)+P (C=co)} and E(Y 0|C =
co) = E(Y |Z=0,A=0)−[P (C=nt)/{P (C=nt)+P (C=co)}]E(Y |Z=1,A=0)P (c=co)/{P (C=nt)+P (C=co)} . The quantities E(Y
1|C = nt) and E(Y 0|C =
at) are not identified. [2]
[24, 25, 26, 27] discuss using the framework described in this section to estimate the effect of a treatment from a
randomized trial with non-compliance where random assignment is used as an IV. Several of these papers consider
the additional complication of subsequent missing outcomes.
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Table 1. The relation of observed groups and latent compliance classes under the monotonicity assumption
Zi Ai Ci
(observed) (observed) (latent)
1 1 co(Complier) or at (Always-taker)
1 0 nt (Never-taker)
0 0 nt (Never-taker) or co (Complier)
0 1 at (Always-taker)
3. Type of Unmeasured Confounding that Can Be Tested For Using an IV
In this section, we discuss what types of unmeasured confounding can be tested for using an IV. Because the
concern about unmeasured confounding is that failure to adjust for unmeasured confounding might bias a treatment
effect estimate, we define there to be unmeasured confounding for a treatment effect estimate if not adjusting for
unmeasured variables would result in a biased estimate of the treatment effect[28]. There are different treatment
effects that are of interest in causal inference, so it is possible for there to be unmeasured confounding for one type
of treatment effect but not for another type of treatment effect.
We will consider testing for unmeasured confounding for three types of treatment effects that are often estimated
in the causal inference literature. For ease of explanation, we will define the treatment effects conditional on the
measured covariates X; the treatment effect over the whole population of interest can be found by averaging the
estimates of the treatment effect for different values of the measured covariates X over the covariate distribution
of the population of interest[32]. The three treatment effects we will consider are the following: (i) the average
causal effect over the whole population with covariatesX (PACEX), τpacex(X) = E(Y 1 − Y 0|X); (ii) the average
causal effect for the treated subjects with covariatesX (TACEX), τtacex(X) = E(Y 1 − Y 0|A = 1,X); and (iii) the
average causal effect for the compliers with covariatesX (CACEX), τcacex(X) = E(Y 1 − Y 0|C = co,X).
We say that there is no unmeasured confounding for a treatment effect τ(X) if the expectation of a straight
comparison between the treated and control subjects’ outcomes conditional onX is equal to τ(X), i.e.,
No unmeasured confounding for τ(X) : E[Y |A = 1,X]− E[Y |A = 0,X] = τ(X). (1)
When (1) holds, a consistent estimate of τ(X) under random sampling is the difference in sample means
of the outcomes for treated (A = 1) and control (A = 0) subjects with covariates X. When X is continuous
or high dimensional, regression methods can be used to estimate E[Y |A,X], and τ(X) can be estimated by
Eˆ[Y |A = 1,X]− Eˆ[Y |A = 0,X] [32]. The bottom line is that when (1) holds, the treatment effect τ(X) can be
estimated consistently from the observed data on treatments, outcomes and covariates; in contrast, when (1) does
not hold, additional information like an IV is needed to deal with unmeasured confounding to obtain consistent
estimates.
We now consider, under what conditions does no unmeasured confounding for the CACEX, τcace(X) =
E(Y 1 − Y 0|C = co), hold? No unmeasured confounding for the CACEX means
E[Y |A = 1,X]− E[Y |A = 0,X] = E[Y 1|C = co,X]− E[Y 0|C = co,X].
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We can decompose the expected values on the left hand side of (1) into parts contributed by the compliance classes:
E(Y |A = 1,X) = E(Y 1|A = 1,X) = P (C = at|X)
P (C = at|X) + P (Z = 1|X)P (C = co|X)E(Y
1|C = at,X) +
P (Z = 1|X)P (C = co|X)
P (C = at|X) + P (Z = 1|X)P (C = co|X)E(Y
1|C = co,X),
E(Y |A = 0,X) = E(Y 0|A = 0,X) = P (C = nt|X)
P (C = nt|X) + P (Z = 0|X)P (C = co|X)E(Y
0|C = nt,X) +
P (Z = 0|X)P (C = co|X)
P (C = nt|X) + P (Z = 0|X)P (C = co|X)E(Y
0|C = co,X). (2)
From (1) and (2), no unmeasured confounding for the CACEX holds if the following two conditions hold
E(Y 1|C = at,X) = E(Y 1|C = co,X) (3)
E(Y 0|C = nt,X) = E(Y 0|C = co,X). (4)
When (3) and (4) both hold, the CACEX can be estimated by comparing the treated and control groups conditional
on X without using an IV. When (3) and/or (4) does not hold, then in most situations, estimating the CACEX
by just comparing the treated and control groups conditional on X without using the IV will produce a biased
estimate. Note that it is possible that such an estimate of the CACEX would be unbiased if, for example, the
bias in Eˆ(Y |A = 1,X) as an estimate of E(Y 1|C = co,X) cancels the bias in Eˆ(Y |A = 0,X) as an estimate of
E(Y 0|C = co,X), but such a situation is unlikely. Thus, for practical purposes, by testing (3) and (4), we are
testing whether there is no unmeasured confounding for the CACEX. We will test (3) and (4) separately because
the violation of one condition but not the other is informative about the nature of the unmeasured confounding; see
the discussion of the NICU study in Section 7.
Because an IV only identifies the CACEX and does not identify the TACEX or the PACEX without further
assumptions[2], we cannot test for no unmeasured confounding for the TACEX or PACEX without further
assumptions. We now discuss further assumptions under which the test of (3)-(4) provides a test for no unmeasured
confounding for the TACEX or PACEX. Consider first the TACEX. There is no unmeasured confounding for the
TACEX if E[Y |A = 1,X]− E[Y |A = 0,X] = E[Y 1 − Y 0|A = 1,X]. If we have an assumption that guarantees
E[Y 1 − Y 0|A = 1,X] = E[Y 1 − Y 0|C = co,X], (5)
then no unmeasured confounding for the TACEX will be equivalent to no unmeasured confounding for the
CACEX, and hence (3)-(4) will guarantee no unmeasured confounding for the TACEX. We will show that such an
assumption that guarantees (5) is that the average treatment effect for the always takers and compliers is the same,
E(Y 1 − Y 0|C = at,X) = E(Y 1 − Y 0|C = co,X), (6)
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Under (6) and Assumptions 1-6 from Section 2.2, we have the following expression for E(Y 1 − Y 0|A = 1,X):
E(Y 1 − Y 0|A = 1,X)
= E(Y 1 − Y 0|A = 1, C = co,X)P (C = co|A = 1,X) + E(Y 1 − Y 0|C = at,X)P (C = at|A = 1,X)
= E(Y 1 − Y 0|Z = 1, C = co,X)P (C = co|A = 1,X) + E(Y 1 − Y 0|C = at,X)P (C = at|A = 1,X)
= E(Y 1 − Y 0|C = co,X)P (C = co|A = 1,X) + E(Y 1 − Y 0|C = at,X)P (C = at|A = 1,X)
= E(Y 1 − Y 0|C = co,X), (7)
where the second to last equality follows from the assumption 2 that Z is independent of potential outcomes and
treatment received conditional onX and the last equality follows from (6) and the fact that
P (C = co|A = 1,X) + P (C = at|A = 1,X) = 1.
Thus, we conclude that under (6), the test of (3)-(4) tests whether there is no unmeasured confounding for the
TACEX. Now consider the PACEX. If we have an assumption that guarantees
E[Y 1 − Y 0|X] = E[Y 1 − Y 0|C = co,X], (8)
then no unmeasured confounding for the PACEXwill be equivalent to no unmeasured confounding for the CACEX.
Using similar reasoning as in (7), such an assumption that guarantees (8) is that the average treatment effect for all
three compliance classes – always takers, compliers and never takers – is the same,
E(Y 1 − Y 0|C = at,X) = E(Y 1 − Y 0|C = co,X) = E(Y 1 − Y 0|C = nt,X), (9)
Thus, under (9), the test of (3)-(4) tests whether there is unmeasured confounding for the PACEX. The assumption
(9) means that the treatment effect is the same for the different compliance classes and thus that there is no effect
modification by compliance class. No effect modification by compliance class will hold if either (a) treatment
effects are homogeneous or (b) treatment effects are heterogeneous but the heterogeneity can be explained by
observed covariates and we include those covariates in the covariate vectorX that we condition on.
In summary, having an IV as defined in Section 2 enables us to test whether there is no unmeasured confounding
for the average treatment effect for compliers (the CACE) by testing (3)-(4). An additional assumption of no effect
modification by compliance class means that this test is also a test of whether there is no unmeasured confounding
for the average treatment effect for the whole population.
In the NICU study (second to last paragraph of introduction and Section 7), there might be effect modification
by compliance class since always takers tend to be sicker babies than compliers or never takers, and might
benefit more from the high technology (e.g., sustained mechanical ventilation) in a high level NICU. Even if
there is effect modification by compliance class, the test of (3)-(4) is still useful in two ways: (i) It tests for
no unmeasured confounding for the CACE, which is useful to know about. The CACE is an important causal
parameter because, by combining the CACE with information about how the treatment effect is expected to
vary between compliers, always takers and never takers, we can predict the effects of increasing or decreasing
access to the treatment[33, 34, 6], i.e., increasing or decreasing access to high level NICUs. If there is unmeasured
confounding for the CACE, then the current study and future studies on the effect of high level NICUs on mortality
and related outcomes should use IV methods to estimate the CACE. But if there is no unmeasured confounding, it
is not necessary to use IV methods; (ii) If (3) or (4) is rejected, then that means there is an unmeasured variable,
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compliance class, which is associated with potential outcomes and treatment even after controlling for the observed
covariates X. This suggests that some key covariate(s) relating to the treatment and outcome remains unmeasured
and it would be worthwhile to try to collect more covariates relating to treatment and outcome if possible.
4. Compliance Class Model Test for Unmeasured Confounding Using an IV
Our approach to testing for no unmeasured confounding is to test (3)-(4) via the following approach:
1. Specify a model for the potential outcome and compliance class distributions.
2. Find the unconstrained maximum likelihood of the model using the EM algorithm.
3. Find the maximum likelihood of the model under the constraints (3) and (4) using the EM algorithm.
4. Test the validity of the constraints (3) and (4) using the likelihood ratio test.
We call our approach the compliance class likelihood ratio test of no unmeasured confounding. We will explain
our approach in detail for binary outcomes and normally distributed outcomes.
4.1. Binary Outcome Model
We consider a logistic model for the outcome in each compliance class/treatment combination and a multinomial
logistic model for the compliance classes. As a starting point, we consider a model in which the effect of the
covariatesX on the outcome is the same across the compliance classes.
Model for the outcome:
P (Y ai = 1|Ci = t,Xi = x) =
exp(κ0,t + κ
T
1 x+ γI(t = co)a)
1 + exp(κ0,t + κT1 x+ γI(t = co)a)
, (10)
where I(·) is the indicator function. The κ0,t’s measure the difference between the compliance classes when the IV
Z = 0 ,κ1 is the effect of x, assumed to be the same across compliance classes and γ is the log odds ratio for the
effect of treatment for compliers.
Model for compliance classes: We consider a multinomial logit model. Let the compliers be the reference
category.
P (Ci = co|Xi = x) = 1
1 + exp(δnt + τTntx) + exp(δat + τ
T
atx)
P (Ci = nt|Xi = x) = exp(δnt + τ
T
ntx)
1 + exp(δnt + τTntx) + exp(δat + τ
T
atx)
P (Ci = at|Xi = x) = exp(δat + τ
T
atx)
1 + exp(δnt + τTntx) + exp(δat + τ
T
atx)
. (11)
We condition on the observed values of the covariates X and the IV Z, and seek to maximize the likelihood
of Y,A|Z,X under the model (10)-(11). We can use the EM algorithm to maximize the likelihood of the model
(10)-(11), where we think of the compliance classes as partially missing data as in ([7, 8, 35, 36]). If we know
the compliance classes, the maximum likelihood estimate (MLE) is easy to compute. In practice, we are not able
to observe the latent compliance classes, so we will use the EM algorithm to obtain the MLE. For the E step,
conditional on observables and parameter estimates in the previous iteration, the expected value of the complete
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data log likelihood lC is
E(lC |Y, Z,A,X) =
n∑
i=1
I(Zi = 1, Ai = 1)logP (Zi = 1|Xi)
+ I(Zi = 1, Ai = 1)ω1[logP (Ci = co|Xi) + log{(PC1i )yi{1− (PC1i )}1−yi}]
+ I(Zi = 1, Ai = 1)(1− ω1)[logP (Ci = at|Xi) + log{(P ati )yi{1− (P ati )}1−yi}]
+ I(Zi = 1, Ai = 0)[logP (Zi = 1|Xi) + logP (Ci = nt|Xi)
+log(Pnti )
yi{1− (Pnti )}1−yi ]
+ I(Zi = 0, Ai = 0)log{1− P (Zi = 1|Xi)}
+ I(Zi = 0, Ai = 0)ω2[logP (Ci = co|Xi) + log{(PC0i )yi{1− (PC0i )}1−yi}]
+ I(Zi = 0, Ai = 0)(1− ω2)[logP (Ci = nt|Xi)] + log{(Pnti )yi{1− (Pnti )}1−yi}]
+ I(Zi = 0, Ai = 1)[log{1− P (Zi = 1|Xi)}+ logP (Ci = at|Xi)
+log{(P ati )yi{1− (P ati )}1−yi}]
where
PC1i = P (Yi = 1|Zi = 1, Ci = co,Xi) =
exp(κ0,co + κ
T
1 x+ γ)
1 + exp(κ0,co + κT1 x+ γ)
P ati = P (Yi = 1|Ci = at,Xi) =
exp(κ0,at + κ
T
1 x)
1 + exp(κ0,at + κT1 x)
Pnti = P (Yi = 1|Ci = nt,Xi) =
exp(κ0,nt + κ
T
1 x)
1 + exp(κ0,nt + κT1 x)
PC0i = P (Yi = 1|Zi = 0, Ci = co,Xi) =
exp(κ0,co + κ
T
1 x)
1 + exp(κ0,co + κT1 x)
ω1 = P (Ci = co|Yi = y, Zi = Ai = 1,Xi)
=
P (Ci = co|Xi)f(Yi|Zi = 1, Ci = co,Xi)
P (Ci = co|Xi)f(Yi|Zi = 1, Ci = co,Xi) + P (Ci = at|Xi)f(Yi|Zi = 1, Ci = at,Xi)
ω2 = P (Ci = co|Yi = y, Zi = Ai = 0,Xi)
=
P (Ci = co|Xi)f(Yi|Zi = 0, Ci = co,Xi)
P (Ci = co|Xi)f(Yi|Zi = 0, Ci = co,Xi) + P (Ci = nt|Xi)f(Yi|Zi = 0, Ci = nt,Xi)
We seek to test the null hypothesis that (3) and (4) hold. Under the model (10)-(11), these two equations can be
simplified as
exp(κ0,at + κ
T
1 x)
1 + exp(κ0,at + κT1 x)
=
exp(κ0,co + κ
T
1 x+ γ)
1 + exp(κ0,co + κT1 x+ γ)
;
exp(κ0,co + κ
T
1 x)
1 + exp(κ0,co + κT1 x)
=
exp(κ0,nt + κ
T
1 x)
1 + exp(κ0,nt + κT1 x)
.
By simple calculation, the null hypothesis that (3) and (4) hold is equivalent to the constraints
κ0,at = κ0,co + γ,
κ0,co = κ0,nt. (12)
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Under the null hypothesis, we can maximize the likelihood using the EM algorithm, where we impose the
constraints (12). The likelihood ratio test of (3) and (4) looks at the difference between the maximized log likelihood
of the unconstrained model (10)-(11) and the maximized log likelihood of the model that constrains (3) and (4) to
hold, i.e., (12) to hold; under the null hypothesis, 2 times this difference follows asymptotically a χ2 distribution
with degrees of freedom equal to the number of extra free parameters in the unconstrained model compared to the
constrained model [37]. For the model (10)-(11), the constraints (12) reduce the number of free parameters by 2
(since κ0,at and κ0,nt are no longer free parameters given κ0,co and γ). Note that for the likelihood ratio test, we are
considering the maximized observed data log likelihood rather than the complete data log likelihood. We can test
(3) and (4) separately by carrying out likelihood ratio tests of the constraints κ0,at = κ0,co + γ and κ0,co = κ0,nt;
for each of these tests, the null distribution of 2 times the log likelihood ratio is χ2 with 1 degree of freedom.
We now consider a binary outcome model where the treatment effect is heterogeneous, that is, the treatment
effect depends on covariatesX.
Model for the outcome that allows for heterogeneous treatment effects: With covariates X, we consider the
following model. Let λt,x denote the log odds that y = 1 when z = 0 for compliance class t and covariate vector
x. Let γx be the log odds ratio that y = 1 for A = 1 vs. A = 0 for compliers with covariates X. The model we
consider is
P (Y ai = 1|Ci = t,Xi = x) =
exp(λt,x + γxI(t = co)a)
1 + exp(λt,x + γxI(t = co)a)
γx = α0 +α
T
1 x
λt,x = κ0,t + κ
T
1,tx. (13)
The model allows for the treatment effect for compliers to depend on x through α1 and for the difference between
the compliance classes when Z = 0 to depend on x through the κ1,t’s.
The expected value of the complete data log likelihood lC and the observed data log likelihood for the binary
outcome model with heterogeneous treatment effect (13) is of the same form as those with homogeneous treatment
effect with different expressions for PC1i ,P
C0
i ,P
at
i and P
nt
i :
PC1i = P (Yi = 1|Zi = 1, Ci = co,Xi) =
exp(λco,x + γx)
1 + exp(λco,x + γx)
P ati = P (Yi = 1|Ci = at,Xi) =
exp(λat,x)
1 + exp(λat,x)
Pnti = P (Yi = 1|Ci = nt,Xi) =
exp(λnt,x)
1 + exp(λnt,x)
PC0i = P (Yi = 1|Zi = 0, Ci = co,Xi) =
exp(λco,x)
1 + exp(λco,x)
By simple calculation, the null hypothesis of no unmeasured confounding (3)-(4) under model (13) is
H0 : κnt = κco,
κat = κco +α, (14)
where κt = (κ0,t,κT1,t) and α = (α0,α1)T .
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4.2. Normal Outcome Model
A normal model for the outcome that allows for a heterogeneous treatment effect that is analogous to (13) is
f(Y ai |Ci = t,Xi = x) = N(κ0,t + κT1,tx+ (α0 +αT1 x)I(t = co)a, σ2) (15)
The null hypothesis of no unmeasured confounding (3)-(4) under the model (15) is (14).
4.3. Computation of MLE– EM and BFGS Optimization
The EM algorithm can sometimes be slow to converge to the MLE near the maximizer of the likelihood[39, 40].
To speed up the convergence to the MLE as in [39, 40, 41], we first run the EM algorithm until it comes close to
convergence and then use the EM estimates as the starting value and maximize the likelihood by a quasi-Newton
method, the Broyden-Fletcher-Goldfarb-Shanno algorithm (BFGS) as implemented in the optim function in R[42].
R functions for computing the EM estimates and BFGS method and implementing our compliance class likelihood
ratio test of no unmeasured confounding are provided in the supplementary materials. Instructions for using the
functions and an example data set are also provided.
5. DWH Test
In this section, we will consider the DWH test statistic for testing for no unmeasured confounding using an IV
and its properties. The conventional DWH test is formulated for a model with a continuous outcome[10, 11, 12].
The DWH test statistic TDWH is the following. Let βˆOLS denote the ordinary least squares (OLS) estimate of the
effect of A on Y controlling for X. Let βˆ2SLS denote the two stage least squares estimate of the effect of A on Y
controlling forX using Z as an IV; βˆ2SLS is computed by by first regressingA on Z,X by least squares and finding
the predicted value Aˆ and then regressing Y on Aˆ,X by least squares. The DWH test statistic is an assessment of
the difference between the OLS and 2SLS estimates of the causal effect of A on Y ,
TDWH =
(βˆOLS − βˆ2SLS)2
ˆV ar(βˆ2SLS)− ˆV ar(βˆOLS)
. (16)
[43]. The variances in (16) are the variances that come from the normal linear regression model and the normal
simultaneous equations model that make the homoskedasticity assumption that V ar(Y 0|X) is equal to V ar(Y 1|X)
and the same for allX[43]. Note that there are several asymptotically equivalent forms of the DWH test which differ
in the way the denominator in (16) is computed; see [43], pp. 50-52. The null hypothesis of the DWH test can
be expressed as the following: there is no unmeasured confounding, i.e., (3) and (4) hold, and the following three
assumptions hold: (i) the average treatment effect for compliers is homogeneous inX, i.e., E(Y 1 − Y 0|C = co,X)
is the same for all X; (ii) E(Y 0|X)) is linear in X; and (iii) a homoskedasticity assumption that V ar(Y 0|X) is
equal to V ar(Y 1|X) and the same for all X. The asymptotic null distribution of TDWH is chi-squared with 1
degree of freedom [10, 12, 11, 43]. Under the null hypothesis for the DHW test, the denominator of the DHW test
statistic (16) times the sample size N converges to the variance of
√
N times (βˆOLS − βˆ2SLS) [12].
We now consider the properties of the DWH test when average treatment effects for compliers are heterogeneous
in X . When average treatment effects for compliers are heterogeneous in X, the DWH test may reject with
probability converging to 1 even when there is no unmeasured confounding. To show this, we will show that βˆOLS
and βˆTSLS can converge to different weighted averages of treatment effects when average treatment effects for
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compliers are heterogeneous in X. Combining this fact with the fact that, under regularity conditions described in
[44], the denominator of the DWH test statistic (16) will converge to 0, shows that TDWH converges in probability
to∞ and rejects with probability 1 even when there is no unmeasured confounding.
We now consider the properties of βˆOLS when (3)-(4) hold and treatment effects are heterogeneous in X.
Let βX = E(Y 1 − Y 0|C = co,X). Suppose E(Yi|Xi, Ai = 0) is linear in Xi. Then E(Y |A = 1,X)− E(Y |A =
0,X) = βX. Then, under the assumption that (3)-(4) hold, we have the following expression for the probability
limit of the OLS estimator where E∗(A|B) is the linear projection of A onto B (i.e., E∗(A|B) = αTB, α =
argminα∗ E(A− (α∗)TB)),
plimβˆOLS =
E[(Ai − E∗(Ai|Xi))(Yi − E∗(Yi|Xi))]
E[(Ai − E∗(Ai|Xi))2] (17)
=
E[(Ai − E∗(Ai|Xi))Yi]
E[(Ai − E∗(Ai|Xi))2] (18)
=
E[(Ai − E∗(Ai|Xi))E(Yi|Xi, Ai)]
E[(Ai − E∗(Ai|Xi))2] (19)
=
E[(Ai − E∗(Ai|Xi))(E(Yi|Xi, Ai = 0) + βXAi)]
E[(Ai − E∗(Ai|Xi))2] (20)
=
E[(Ai − E∗(Ai|Xi))2βX]
E[(Ai − E∗(Ai|Xi))2] , (21)
where we used the fact that E ((Ai − E∗(Ai|Xi))Xi) = 0 to derive (18) and (21) and we iterated expectations over
Xi and Ai to derive (19). (21) shows that the OLS estimator converges to a weighted average of treatment effects
at different values of X, where the values of X that get the most weight are those where E[(Ai − E∗(Ai|Xi))2]
is largest. [38] derive similar expressions assuming E(Ai|Xi) is linear in Xi. If E(Ai|Xi) is linear in X, then
E[(Ai − E∗(Ai|Xi))2] is the conditional variance of A given X. If E(Yi|Xi, Ai = 0) is not linear in Xi, then
plimβˆOLS equals (21) plus
E[(Ai−E∗(Ai|Xi))E(Y 0|X)]
E[(Ai−E∗(Ai|Xi))2] .
We now consider the properties of βˆTSLS when (3)-(4) hold but treatment effects are heterogeneous in X. We
assume E(A|X, Z) is linear in X, Z. Then the plim of βˆTSLS is the plim of the coefficient on E(A|X, Z) in the
regression of Y on E(A|X, Z) and X. By the same reasoning as in (17)-(21), this plim is the weighted average
of βX over the distribution ofX, weighted by E[{E(A|X, Z)− E∗(E(A|X, Z)|X)}2]. Under the assumption that
E(A|X, Z) is linear in X, Z, these weights equal the conditional variance of E(A|Z,X) given X, which equals
P (C = co|X)2P (Z = 1|X)(1− P (Z = 1|X)). Thus,
plimβˆTSLS = E[P (C = co|Xi)2P (Zi = 1|Xi)(1− P (Zi = 1|Xi))βX]/
E[P (C = co|Xi)2P (Zi = 1|Xi)(1− P (Zi = 1|Xi))]. (22)
Thus, the TSLS estimator converges to a weighted average of treatment effects at different values of X, where the
values of X that tend to get the most weight are those for which the proportion of compliers is highest. A value of
X at which there are no compliers gets zero weight.
From (21) and (22), the numerator of the DWH test statistic (16) converges in probability to
E[P (C = co|X)2P (Z = 1|X)(1− P (Z = 1|X))βX]
E[P (C = co|X)2P (Z = 1|X)(1− P (Z = 1|X))] −
E[(A− E∗(A|X))2βX]
E[(A− E∗(A|X))2] . (23)
and the denominator of (16) converges in probability to 0 under regularity conditions. Thus, under the regularity
conditions, when (23) is not equal to zero, TDWH converges in probability to∞. In summary, even when there is
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no unmeasured confounding, we have shown that βˆOLS and βˆTSLS can converge to different weighted averages
of treatment effects when average treatment effects for compliers are heterogeneous in X, and consequently the
DWH test statistic (16) can converge in probability to∞.
6. Simulation Study
6.1. Normal Outcomes
We will compare the compliance class likelihood ratio test of no unmeasured confounding developed in Section 4
to the DWH test in a simulation study under the normal outcome model (15). We will consider one binary covariate
X . We consider three scenarios:
I The null hypothesis of no unmeasured confounding for the CACE, i.e., (3)-(4), holds, which is equivalent for
the normal outcome model to (14) holding. Additionally, the complier treatment effect is homogeneous in X ,
i.e., α1 = 0. Here we expect that both the DWH test and our test will have a 0.05 Type I error rate.
II The null hypothesis of no unmeasured confounding for the CACE holds but the treatment effect is
heterogeneous in X , i.e., α1 ̸= 0. Here we expect our test will have a 0.05 Type I error rate but the DWH
test will have a greater than 0.05 Type I error rate.
III The null hypothesis of no unmeasured confounding for the CACE does not hold.
The parameters for (15) for each scenario are shown in Table 2. The sample size for each simulation scenario is
1000 and 1000 simulations were carried out for each scenario. For all the scenarios, the IV Z was generated as a
Bernoulli random variable with
P (Zi = 1|Xi = x) = exp (−1 + 2x)
1 + exp (−1 + 2x) .
The parameters −1 and 2 were chosen so that P (Z|X) and the marginal probability of Z = 1 is about 12 . Also, for
all the scenarios, the model for the compliance class is as follows:
P (Ci = at|Xi = x) = P (Ci = nt|Xi = x) = exp(−2.5 + 3.5x)
1 + 2 exp(−2.5 + 3.5x)
P (Ci = co|Xi = x) = 1
1 + 2 exp(−2.5 + 3.5x) (24)
From section 5, we know that the OLS estimator is a weighted average of the treatment effects with conditional
variance V ar(Ai|Xi) as weights whereas the 2SLS estimator is a weighted average of the treatment effects where
the weights are related with P (Ci = co|Xi). The compliance class model (24) was chosen so that these two
sets of weights differ. In scenario II, we have P (Ci = co|Xi = 1) ≈ 0.16, P (Ci = co|Xi = 0) ≈ 0.85 whereas
V ar(Ai|Xi = 1) ≈ 0.25, V ar(Ai|Xi = 0) ≈ 0.22.
Table 3 shows the bias of the MLE estimates over the whole parameter space for the three simulation scenarios as
well as the bias of the restricted MLE estimates (RMLE) under the constraint (14) of no unmeasured confounding
for the CACE. The MLE estimates are approximately unbiased for all three scenarios. The RMLE estimates are
approximately unbiased for the first two scenarios where no unmeasured confounding for the CACE holds, but are
substantially biased in Scenario 3, where no unmeasured confounding for the CACE does not hold.
Table 4 shows the rejection rates of the compliance class model likelihood ratio test and the DWH test for the
three scenarios. For scenario I, in which the null hypothesis of no unmeasured confounding for the CACE holds
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Scenario I Scenario II Scenario III
κ0,at 0.8 0.8 1.5
κ1,at 1 0 1
κ0,co 0.3 0.3 0.3
κ1,co 1 1 1
κ0,nt 0.3 0.3 -1
κ1,nt 1 1 2
α0 0.5 0.5 0.5
α1 0 -1 -1
Table 2. Parameters of Normal Outcome Model
Scenario I Scenario II Scenario III
MLE RMLE MLE RMLE MLE RMLE
δnt -0.0477146 -0.0544274 -0.0476901 -0.0543439 0.0156288 -0.0543725
τnt 0.1013498 0.0999249 0.1007317 0.0997708 0.0128341 0.0997589
δat -0.0095424 -0.0104721 -0.0095449 -0.0104576 0.0038682 -0.0104442
τat 0.0519741 0.0442860 0.0513301 0.0441942 0.0009426 0.0441336
κ0,at 0.0058613 -0.0005772 0.0058594 -0.0005727 0.0037276 -0.5367873
κ1,at -0.0062825 0.0006663 -0.0063618 0.0006561 0.0014474 0.1747882
κ0,co -0.0018516 -0.0020254 -0.0018565 -0.0020229 0.0006294 -0.1324547
κ1,co -0.0166094 0.0037380 -0.0142488 0.0037335 0.0596318 -0.1388161
κ0,nt -0.0031835 -0.0021490 -0.0031585 -0.0021505 0.0111069 1.1674984
κ1,nt 0.0066654 0.0039132 0.0064480 0.0039194 0.0093282 -1.1386382
α0 -0.0010242 0.0016277 -0.0010176 0.0016200 0.0069120 0.2959712
α1 0.0326921 -0.0031748 0.0307796 -0.0031632 0.0566909 1.3134260
σ2 -0.0135517 -0.0025765 -0.0135338 -0.0025765 0.0079252 0.0920937
Table 3. Bias of Sample mean of δt, τt, λt,γt and σ2 with 1000 simulations of sample size 1000 for the normal
model
Scenario I II III
r̂rα=0.01 r̂rα=0.05 r̂rα=0.01 r̂rα=0.05 r̂rα=0.01 r̂rα=0.05
DWH test 0.006 0.042 0.662 0.853 0.98 0.997
LR test 0.014 0.053 0.014 0.052 1 0.999
Table 4. Empirical rejection rates r̂rα with type I error α for the normal outcome model with 1000 simulations.
and also the treatment effect for compliers is homogeneous inX , both the compliance class model likelihood ratio
test and the DWH test have empirical rejection rates close to their nominal Type I error level. For scenario II, in
which the null hypothesis of no unmeasured confounding for the CACE holds but the treatment effect for compliers
is heterogeneous in X , the compliance class model likelihood ratio test has an empirical rejection rate close to its
nominal Type I error rate but the DWH test rejects far too often, e.g., it rejects 0.853 of the time when the nominal
type I error rate is 0.05. For scenario III, in which the null hypothesis of no unmeasured confounding for the CACE
does not hold, both tests have high power with the compliance class model likelihood ratio test having slightly
higher power. In summary, the simulation study results show that the compliance class model likelihood ratio test
has advantages over the DWH test: the compliance class model likelihood ratio test has comparable power to the
DWH test, but keeps close to the correct Type I error rate when treatment effects are heterogeneous in X, unlike
the DWH test.
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The compliance class model likelihood ratio test (the LR test) is more computationally intensive than the DWH
test. For the first scenario of the simulation study, on an Optiplex 780 computer with Intel Core Duo CPU E8400@
3.00 GHZ and 4 GB Ram, the DWH test took an average of 0.013 CPU seconds while the LR test took an average
of 53.7 CPU seconds. The DWH test is faster than the compliance class likelihood ratio test, but the LR test is
not prohibitively slow, taking less than a minute. Although the DWH test is faster, the DWH test does not work
for models with heterogeneous treatment effects. When dealing with real data, we do not know whether there are
heterogeneous treatment effects. When computational efficiency is not the main concern, we suggest to test for no
unmeasured confounding using the LR test.
6.2. Binary Outcomes
In this section, we study the performance of the compliance class likelihood ratio for no unmeasured confounding
for binary outcomes developed in Section 4.1 We do not consider the DWH since the DWH test assumes normal
outcomes rather than binary outcomes. We simulate the binary outcome model as in (10) and estimate the
parameters by the EM algorithm for the binary outcome. As for the simulation for normal outcomes, we consider
three scenarios: (I) the null hypothesis of no unmeasured confounding for the CACE holds and the complier
treatment effect is homogeneous in X; (II) the null hypothesis of no unmeasured confounding for the CACE
holds and the complier treatment effect is heterogeneous in X; and (III) the null hypothesis of no unmeasured
confounding for the CACE does not hold. The parameters for (10) for each scenario are shown in Table 5. The
sample size for each simulation scenario is 1000 and 1000 simulations were carried out for each scenario. For all
the scenarios, the IV Z was generated as a Bernoulli random variable with
P (Zi = 1|Xi = x) = exp (−2 + x)
1 + exp (−2 + x) .
The parameters −2 and 1 were chosen so that P (Z|X) and the marginal probability of Z = 1 is about 12 . Also, for
all the scenarios, the model for the compliance class is as follows:
P (Ci = at|Xi = x) = exp(−1.5 + 0.1x)
1 + exp(−1.5 + 0.1x) + exp(−1 + 0.05x)
P (Ci = nt|Xi = x) = exp(−1 + 0.05x)
1 + exp(−1.5 + 0.1x) + exp(−1 + 0.05x)
P (Ci = co|Xi = x) = 1
1 + exp(−1.5 + 0.1x) + exp(−1 + 0.05x) (25)
Table 6 shows the bias of the MLE estimates over the whole parameter space for the three simulation scenarios as
well as the bias of the restricted MLE estimates (RMLE) under the constraint (14) of no unmeasured confounding
for the CACE. The MLE estimates are approximately unbiased for all three scenarios. The RMLE estimates are
approximately unbiased for the first two scenarios where no unmeasured confounding for the CACE holds, but are
substantially biased in Scenario 3, where no unmeasured confounding for the CACE does not hold.
Table 7 shows the rejection rates of the compliance class model likelihood ratio test for the three scenarios. For
scenario I and scenario II,in which the null hypothesis of no unmeasured confounding for the CACE holds, the
compliance class model likelihood ratio test has an empirical rejection rate close to its nominal Type I error rate.
For scenario III, in which the null hypothesis of no unmeasured confounding for the CACE does not hold, the
compliance class model likelihood ratio test has high power.
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Scenario I Scenario II Scenario III
κ0,at 0 0 -2
κ1,at 1 0 1
κ0,co -0.5 -0.5 -0.5
κ1,co 1 1 1
κ0,nt -0.5 -0.5 -1
κ1,nt 1 1 0.5
α0 0.5 0.5 0.5
α1 0 -1 -1
Table 5. Parameters of Binary Outcome Model
Scenario I Scenario II Scenario III
MLE RMLE MLE RMLE MLE RMLE
δnt -0.009862 -0.010882 -0.005490 -0.006288 0.000971 -0.004599
τnt 0.003475 0.003582 0.003023 0.002972 -0.000865 0.001501
δat -0.009214 -0.009853 -0.002856 -0.003171 -0.001430 -0.006231
τat -0.001601 -0.001790 0.001344 0.000897 -0.004487 -0.001151
κ0,at -0.025060 -0.015066 -0.005103 -0.005550 -0.125930 1.268413
κ1,at 0.074988 0.013357 0.008522 0.001488 0.076193 -0.718085
κ0,co -0.032044 -0.007961 -0.043709 -0.011160 -0.028737 -0.116232
κ1,co 0.046542 0.008069 0.052011 0.009544 0.046948 -0.419943
κ0,nt -0.088219 -0.007961 -0.086033 -0.011160 -0.033784 0.383768
κ1,nt 0.066193 0.008069 0.067434 0.009544 0.017085 0.080057
α0 0.032538 -0.007106 0.035052 0.005610 0.018919 -0.615355
α1 0.098868 0.005288 -0.052364 -0.008057 -0.047160 0.701858
Table 6. Bias of Sample mean of δt, τt, λt,γt and σ2 with 1000 simulations of sample size 1000 for the binary
outcome model
Scenario I II III
r̂rα=0.01 r̂rα=0.05 r̂rα=0.01 r̂rα=0.05 r̂rα=0.01 r̂rα=0.05
LR test 0.050 0.014 0.013 0.055 0.994 0.997
Table 7. Empirical rejection rates r̂rα with type I error α for the exponential(1) distribution with 1000 simulations.
7. Application to Study of High-Level NICUs vs. Lower-Level NICUs
We obtained birth certificates from all deliveries occurring in Pennsylvania between 1995-2005. The Pennsylvania
Department of Health linked these birth certificates to death certificates using name and date of birth, and then
de-identified the records. We then matched over 98% of birth certificates to maternal and newborn hospital records
using methods described in [21]. Over 80% of the unmatched birth certificate records were missing hospital,
suggesting a birth at home or a birthing center. The unmatched records had similar gestational age and racial/ethnic
distributions to the matched records. The Institutional Review Boards of The Children’s Hospital of Philadelphia
and the Pennsylvania Department of Health approved this study.
Infants included in this study had a gestational age between 23 and 37 weeks, and a birth weight between 400
to 8000 grams. Birth records were excluded if the birth weight was more than 5 standard deviations from the mean
birth weight for the recorded gestational age in the cohort. There are 192,078 infants in the final cohort. The primary
outcome for this study is neonatal death, defined as any death during the initial birth hospitalization. The IV we
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consider is Z = 1 if a mother’s excess travel time to the nearest high level NICU compared to the nearest hospital
is 10 minutes or less, Z = 0 if her excess travel time is more than 10 minutes. The measured confounders X are
birth weight, an indicator for whether birth weight is missing, the month of pregnancy that prenatal care started,
an indicator for whether this month is missing, mother’s education, an indicator for whether mother’s education
is missing and an indicator for whether the mother went into labor prematurely (as compared to having a planned
premature birth by induced labor or C-section).
Mother’s excess travel time Z plausibly satisfies the IV assumptions 1-6 in Section 2.2 for the following reasons.
First, for the stable unit treatment value assumption (SUTVA), whether one mother lives near a high level NICU or
delivers at a high level NICU is unlikely to affect another mother and her infant, so SUTVA is plausible. Second,
for the IV being independent of unmeasured confounding, women do not expect to have a premature delivery, and
thus conditional on measured socioeconomic variables such as mother’s education, women do not choose where to
live based on distance to a high level NICU, making independence from unmeasured confounding plausible[21].
Third, the exclusion restriction (no direct effect of excess travel time) is plausible because most mothers have time
to deliver at either the nearest high level or low level NICU so that the marginal travel time should not directly
affect outcomes[21]. Fourth, for the IV affecting the treatment, excess travel time is correlated with whether a
mother delivers at a high level NICU because a mother typically obtains prenatal care from and would prefer to
deliver at a close by facility[23]. Fifth, for the monotonicity assumption, if a mother would travel to go to a high
level NICU when living more than ten minutes further from the high level NICU than the nearest low level NICU,
she would presumably also travel to the high level NICU if it were less than ten minutes further than the nearest low
level NICU; thus, monotonicity is plausible. Sixth, for the consistency assumption, although it is unlikely to hold
exactly since different high level NICUs may differ in their level of care and different low level NICUs may differ
in their level of care, it plausibly holds approximately; see [45] for discussion about interpreting causal estimates
when consistency does not hold exactly. In summary, mother’s excess travel time is a plausible IV.
[21] and [9] have used mother’s excess travel time as an IV to estimate the effect of a premature infant being
delivered in a high level NICU vs. a low level NICU for compliers, i.e., E(Y 1 − Y 0|C = co). Here our focus is on
using mother’s excess travel time to test whether there is unmeasured confounding. Because the outcome, neonatal
death, is binary, we consider the binary outcome models of Section 4.1. First, we test the null hypothesis that
there are homogeneous treatment effects in terms of the measured covariates X vs. the alternative that there are
heterogeneous treatment effects, i.e., test H0 : α1 = 0 vs. Ha : α1 ̸= 0 in model (13). We use a likelihood ratio
test to test this. The test yields a p-value < 0.001, providing evidence of heterogeneous treatment effects. When
there are heterogeneous treatment effects, the DWH test may not properly control the Type I error rate, but the
compliance class likelihood ratio test does properly control the Type I error rate (see Sections 5-6), and hence we
will use the compliance class likelihood ratio to test for unmeasured confounding.
Table 8 shows the results of the compliance class likelihood ratio test for unmeasured confounding. There is
strong evidence (p-value < 0.001) that (3) is violated, that is always takers have different risks of death than
compliers conditional on the measured confounders X when both deliver at high level NICUs. There is also
evidence that never takers have different risks of death than compliers, that is (4) is violated, but the evidence is
not as strong as for always takers (p-value = 0.012 compared to p < 0.001). In summary, there is strong evidence
of some unmeasured confounding.
Table 9 shows, for various combinations of the measured confounders X, the estimated probabilities of death
from the model (13) for never takers delivering at low level NICUs, compliers delivering at low level NICUs,
compliers delivering at high level NICUs and always takers delivering at high level NICUs. For example, for an
infant weighing 1500 grams, whose mother started prenatal care in the second month of pregnancy, whose mother
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Test Statistic Degrees of Freedom p-value
Test of (3) 75.9 8 < 0.001
Test of (4) 19.6 8 0.012
Test of (3) and (4) 76.6 16 < 0.001
Table 8. Compliance class likelihood ratio test of no unmeasured confounding for the NICU study.
Birthweight Month Mother’s Pnt Pco,0 Pco,1 Pat
Prenatal Care Education
Started
1500 2 High School 0.057 0.047 0.030 0.052
2000 2 High School 0.019 0.018 0.011 0.017
2500 2 High School 0.006 0.006 0.004 0.005
1500 4 High School 0.056 0.051 0.031 0.049
2000 4 High School 0.019 0.019 0.011 0.016
2500 4 High School 0.006 0.007 0.004 0.005
1500 2 College 0.040 0.028 0.018 0.045
2000 2 College 0.013 0.010 0.007 0.015
2500 2 College 0.004 0.004 0.002 0.005
1500 4 College 0.041 0.031 0.019 0.043
2000 4 College 0.014 0.011 0.007 0.014
2500 4 College 0.004 0.004 0.002 0.004
Table 9. Estimated Probability of Death For Different Compliance classes with Different Covariate Values. For all
sets of covariate values, the mother is assumed to have gone into premature labour, where Pnt = P (Y 0 = 1|C =
nt),Pco,0 = P (Y 0 = 1|C = co),Pco,1 = P (Y 1 = 1|C = co),Pat = P (Y 1 = 1|C = co).
has a high school education and whose mother went into preterm labor, the risk of death is 0.054 for never takers
delivering at low level NICUs, 0.051 for compliers delivering at low level NICUs, 0.031 for compliers delivering
at high level NICUs and 0.052 for always takers delivering at high level NICUs. This pattern of similar death rates
for never takers and compliers delivering at low level NICUs, considerably lower death rates for compliers vs.
always takers delivering at high level NICUs and considerably lower death rates for compliers delivering at high
level NICUs vs. low level NICUs holds for all combinations of the measured confoundersX.
8. Conclusions and Discussion
We have developed a test of whether there is unmeasured confounding when an instrumental variable (IV) is
available. Our test has correct type I error rate unlike the Durbin-Wu-Hausman (DWH) test, which can have inflated
type I error rates when there is treatment effect heterogeneity. An important additional advantage of our approach
over the DWH test is that it breaks up the test into the two parts (3) and (4), providing more information. For the
NICU study, we found evidence that never takers are at a little higher risk of death than compliers when both groups
are delivered at low level NICUs and that always takers are at a much higher risk of death than compliers when
both groups are delivered at high level NICUs. This latter piece of evidence means that infants who are bypassing
local hospitals to go to high level NICUs (i.e., always takers) have unmeasured confounders that makes them have
a higher risk of death than infants who would only deliver at a high level NICU if living relatively near to one (i.e.,
compliers). This suggests that there is some triaging in the way infants are delivering at high level NICUs vs. low
level NICUs; future studies could examine how effective this triaging system is.
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We have tested the null hypothesis that there is no unmeasured confounding. In some settings, we may instead
want to do an equivalence test of the null that the unmeasured confounding is greater than or equal to a specified
magnitude vs. the alternative that it is less than this magnitude. For example, instead of testing the null hypothesis
of (3), we may want to test
H0 : E(Y
1|C = at,X)− E(Y 1|C = co,X) ≥ ϵ or ≤ −ϵ vs.
Ha : −ϵ < E(Y 1|C = at,X)− E(Y 1|C = co,X) < ϵ, (26)
where ϵ is an equivalence margin specified by a subject matter expert. We can test (26) using the two one-sided
test procedure [46, 47]. We test H0 in (26) at level α by testing H10 : E(Y 1|C = at,X)− E(Y 1|C = co,X) ≥ ϵ
and obtaining one-sided p-value P1 and testing H20 : E(Y 1|C = at,X)− E(Y 1|C = co,X) ≤ −ϵ and obtaining
one-sided p-value P2, and then rejecting H0 if max(P1, P2) ≤ α. Similarly, we could implement an equivalence
test of (4)
The compliance class likelihood ratio test of no unmeasured confounding developed in this paper makes use of
assumptions about the probability distribution of the outcome within compliance classes. In this paper, we have
considered normal and binary outcomes. In our application, we know that the outcome is binary, but in applications
in which the outcome is continuous, we may not know the probability distribution of the outcome. Our test may not
perform well when the assumed probability distribution of the outcome does not hold and it is useful to evaluate
the goodness of fit of the assumed probability distribution of the outcome. [49] developed an approach to evaluate
the goodness of fit for a principal stratification model. If the goodness of fit is not adequate, a different probability
distribution model for the outcome can be considered. Our test can easily be extended to non-normal outcome
models by using an analogous EM algorithm as in Section 4.1. Also, rather than assuming a parametric model
for the outcome distribution, a semiparametric model can be assumed such as the semiparametric density ratio
model[7].
In this paper, we have focused on a binary IV. Although mother’s excess travel time is a continuous variable, we
dichotomized it to be a binary IV (whether the excess time is larger than 10 or not). In practice, it’s common that
investigators dichotomize multi-level IVs into binary IVs as clinicians may find it easier to think about the validity
of the IV assumptions and the interpretation of the IV estimate in terms of a binary IV. However, our method can
be extended to a multi-level IV. Suppose the multi-level IV satisfies an extended monotonicity assumption that an
individual’s potential level of treatment is an increasing function of the level of the IV, Azi ≥ Az
′
i if z ≥ z′[48]. Let
Ti be the smallest z for which Azi = 1 where Ti = −∞ if Azi = 1 for all z and Ti =∞ if Azi = 0 for all z. To test
for no unmeasured confounding, we can formulate a parametric model for Y 1i |Ti,Xi and Y 0i |Ti,Xi as in [48], fit
the model by maximum likelihood and test (3)-(4).
19
9. Appendix
The complete data log likelihood for the binary outcome is
lC =
n∑
i=1
I(Zi = 1, Ai = 1)logP (Zi = 1|Xi)
+ I(Zi = 1, Ai = 1, Ci = co)[logP (Ci = co|Xi) + logf(Yi = y|Zi = 1, Ci = co,Xi)]
+ I(Zi = 1, Ai = 1, Ci = at)[logP (Ci = at|Xi) + logf(Yi = y|Zi = 1, Ci = at,Xi)]
+ I(Zi = 1, Ai = 0)[logP (Zi = 1|Xi) + logP (Ci = nt|Xi) + logf(Yi = y|Zi = 1, Ci = nt,Xi)]
+ I(Zi = 0, Ai = 0)log{1− P (Zi = 1|Xi)}
+ I(Zi = 0, Ai = 0, Ci = co)[logP (Ci = co|Xi) + logf(Yi = y|Zi = 0, Ci = co,Xi)]
+ I(Zi = 0, Ai = 0, Ci = nt)[[logP (Ci = nt|Xi) + logf(Yi = y|Zi = 0, Ci = nt,Xi)]
+ I(Zi = 0, Ai = 1)[log{1− P (Zi = 1|Xi)}+ logP (Ci = at|Xi) + logf(Yi = y|Zi = 0, Ci = at,Xi)].
The observed data log likelihood for the binary outcome is
l =
n∑
i=1
I(Zi = 1, Ai = 1) logP (Zi = 1|Xi)
+
n∑
i=1
I(Zi = 1, Ai = 1) log[P (Ci = at|Xi)(P ati )yi(1− P ati )1−yi + P (Ci = co|Xi)(PC1i )yi(1− PC1i )1−yi ]
+
N∑
i=1
I(Zi = 1, Ai = 0)[logP (Zi = 1|Xi) + logP (Ci = nt|Xi)(Pnti )yi(1− Pnti )1−yi ]
+
N∑
i=1
I(Zi = 0, Ai = 1)[logP (Zi = 0|Xi) + logP (Ci = at|Xi)(P ati )yi(1− P ati )1−yi ]
+
n∑
i=1
I(Zi = 0, Ai = 0) logP (Zi = 0|Xi)
+
n∑
i=1
I(Zi = 0, Ai = 0) log[P (Ci = nt|xi)(Pnti )yi(1− Pnti )1−yi + P (Ci = co|xi)(PC0i )yi(1− PC0i )1−yi ].
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